Spruce Biosciences Inc

NASDAQ:SPRBUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Contact Information

Headquarters

611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO, CA, United States 94080

Phone

415-655-4168

Fax

302-636-5454

Executives

Executive Chairman of the Board

Michael Grey

President, Chief Financial Officer

Samir Gharib

Director

Javier Szwarcberg

Chief Medical Officer

Ralph Charlton

Independent Director

Tiba Aynechi